Abstract
BackgroundCamrelizumab and chemotherapy demonstrated durable antitumor activity with a manageable safety profile as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have